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Purpose: To determine which factors contributed to the Digital




This project was HIPAA compliant and institutional review
board approved. Seven radiologist readers reviewed the
film hard-copy (screen-film) and digital mammograms in
DMIST cancer cases and assessed the factors that contrib-
uted to lesion visibility on both types of images. Two
multinomial logistic regression models were used to ana-
lyze the combined and condensed visibility ratings as-
signed by the readers to the paired digital and screen-film
images.
Results: Readers most frequently attributed differences in DMIST
cancer visibility to variations in image contrast—not differ-
ences in positioning or compression—between digital and
screen-film mammography. The odds of a cancer being
more visible on a digital mammogram—rather than being
equally visible on digital and screen-film mammograms—
were significantly greater for women with dense breasts
than for women with nondense breasts, even with the data
adjusted for patient age, lesion type, and mammography
system (odds ratio, 2.28; P  .0001). The odds of a cancer
being more visible at digital mammography—rather than
being equally visible at digital and screen-film mammogra-
phy—were significantly greater for lesions imaged with the
General Electric digital mammography system than for
lesions imaged with the Fischer (P  .0070) and Fuji (P 
.0070) devices.
Conclusion: The significantly better diagnostic accuracy of digital mam-
mography, as compared with screen-film mammography,
in women with dense breasts demonstrated in the DMIST
was most likely attributable to differences in image con-
trast, which were most likely due to the inherent system
performance improvements that are available with digital
mammography. The authors conclude that the DMIST re-
sults were attributable primarily to differences in the dis-
play and acquisition characteristics of the mammography
devices rather than to reader variability.
 RSNA, 2009
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In the National Cancer Institute andAmerican College of Radiology Imag-ing Network (ACRIN)-sponsored Dig-
ital Mammographic Imaging Screening
Trial (DMIST), participants underwent
both digital mammography and screen-
film mammography between September
2001 and November 2003. Digital mam-
mography was performed by using five
digital systems from four manufactur-
ers—Senoscan-Dx (Fischer, Denver,
Colo), Computed Radiography (Fuji, To-
kyo, Japan), Senographe (General Elec-
tric, Waukesha, Wis), Lorad CCD-OT
(Hologic, Bedford, Mass), and Lorad Se-
lenia-MG (Hologic) (1)—with each wom-
an’s mammograms interpreted indepen-
dently by different radiologists. Analysis
was based on the results for 42 760
women who underwent breast biopsy or
follow-up more than 10 months after they
entered the study and received a diagno-
sis of cancer within 15 months after study
entry (2). The diagnostic accuracy of dig-
ital mammography was found to be signif-
icantly superior to that of screen-film
mammography for women with dense
breasts, women younger than 50 years,
and pre- and perimenopausal women (2).
A nonsignificant trend toward better di-
agnostic accuracy with screen-film mam-
mography than with digital mammogra-
phy was observed in women aged 65
years or older who had fatty breasts (3).
Our purpose in this study was to deter-
mine which factors contributed to the
DMIST cancer detection results.
Materials and Methods
Our Health Insurance Portability and Ac-
countability Act–compliant project was
approved by the institutional review
boards of the University of North Caro-
lina at Chapel Hill and ACRIN. The digital
mammograms of 335 DMIST cancers
were processed for use in our study by
each manufacturer with use of techniques
available at the time of DMIST. Although
the University of North Carolina at
Chapel Hill has a research agreement
with General Electric, no other financial
or equipment support for this study was
provided by the manufacturers. Data
were controlled by study personnel who
were not consultants to the digital mam-
mography manufacturers at any time.
One author (R.E.H.) was recently hired
as a consultant to GE Healthcare
(Waukesha, Wis).
DMIST Case Mix in Current Study
Some of the 335 DMIST cancer cases
were not reviewed by all readers because
screen-film mammograms were not avail-
able owing to intermittent requests for
them by participating sites for patient
care purposes. A total of 307 cases with
both digital and screen-film mammo-
grams were available for our study. These
cases included 294 cases with one cancer
and 13 cases with two cancers; thus, a
total of 320 cancers were available for
review. The cases with two cancers were
retained to provide readers with a typical
clinical case mix. All soft-copy (digital
mammography) cases were available in a
Digital Imaging and Communications in
Medicine format and varied only with re-
spect to the machine used (Senographe,
Lorad Selenia-MG, Senoscan-Dx, Com-
puted Radiography, or Lorad CCD-OT).
The images in all cases were downloaded
for soft-copy review to a soft-copy review
workstation (Sectra IDS5.X; Sectra
North America, Shelton, Conn). Readers
defined their own hanging protocols,
which were set up by a research assistant
(E.B.C.). Each reader rated 302–306
cases, which involved 308–319 cancers.
One radiologist (E.D.P.) with 23
years of experience in breast imaging re-
corded the location of each cancer on the
basis of visual inspection and information
provided in the radiology and pathology
reports by recording the visibility of the
lesion on both screen-film and digital
mammograms, the size of the lesion mea-
sured on the screen-film image (or, if it
was not visible on the film hard-copy im-
age, as measured on the digital image),
and the structural characteristics of the
lesion (presence of mass, calcifications,
architectural distortion, focal asymmetry
or other finding according to Breast Im-
aging Reporting and Data System [BI-
RADS] [4] descriptors). The radiologist
also created an acetate overlay that encir-
cled either all the lesions or the location of
the known cancers on the basis of her
review of the mammograms or informa-
tion in the other DMIST records.
Nine additional radiologists (J.K.B.,
L.L.F., R.A.J., M.A.K., C.M.K., Y.L.,
W.P., D.P., S.C.Y.) participated in the
reader study. Two readers (W.P.,
S.C.Y.) reported having no previous ex-
perience with digital mammography and




ACRIN  American College of Radiology Imaging Network
CI  confidence interval
DMIST  Digital Mammographic Imaging Screening Trial
OR  odds ratio
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Advance in Knowledge
 The Digital Mammographic Imag-
ing Screening Trial results were
most likely attributable to differ-
ences in image contrast, which
were most likely due to the inher-
ent system performance improve-
ments that are available with digi-
tal mammography rather than to
differences in positioning, com-
pression, or reader skill.
Implication for Patient Care
 These study results support the
use of digital mammography in
place of screen-film mammogra-
phy in women with dense breasts,
women younger than 50 years,
and pre- and perimenopausal
women.
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thus did not participate in our primary
analysis because of the likelihood that
their lack of digital mammography expe-
rience would bias their opinions in favor
of screen-film mammography. The seven
other readers had 4–10 years experience
interpreting digital mammograms and
5–30 years experience in breast imaging.
All readers had experience using the
General Electric system, and all but one
had experience using more than one dig-
ital mammography system—five readers
had experience using the Fischer unit;
three, experience using the Fuji unit; two,
experience using the Hologic machines;
and one each, experience with only Sie-
mens (Erlangen, Germany) or Hologic
systems. Our study took place at a single
site (University of North Carolina Bio-
medical Research Imaging Center), and
each reader participated for at least 2
days. A multiviewer (Mammoscope
MS614A; RADx, Plano, Tex) was loaded
with the screen-film mammography
cases. The digital mammograms were
displayed on the soft-copy review work-
station and processed according to algo-
rithms that were available at the time of
DMIST, including Premium View (Gen-
eral Electric), which was available at the
DMIST sites for only the last 4 months of
case accrual. The screen-film and digital
mammograms were displayed simulta-
neously, next to each other, with minimal
glare. A 2 magnifying glass and stan-
dard soft-copy image manipulations
(brightness, contrast, magnification,
zoom, and pan) were available.
The readers were informed that all
cases included known malignancies and
were provided with the annotated acetate
overlay used to identify the actual cancer
locations. They then rated the relative vis-
ibility of the known cancers on the
screen-film mammograms versus the vis-
ibility on the digital mammograms. The
visibility of each lesion with each modality
was graded on a five-point scale by using a
visual analogue table, on which the read-
ers marked a point that corresponded to
the relative visibility of the lesion on both
types of images (digital and screen film).
If readers rated the visibility of a le-
sion as different between screen-film
mammography and digital mammogra-
phy, they recorded their opinion as to
why they believed the visibility differed
between the two modalities by checking
all applicable reasons from the following
list: positioning differences, compression
differences, location of cancer in dense
tissue, overlapping parenchyma obscured
lesion with one modality but not with the
other, location of lesion in subcutaneous
fat, location of lesion in the thickest part
of the breast, lesion characteristics were
more evident with one modality than with
the other (ie, more calcifications were
seen, calcification shapes were more ob-
vious, suspicious mass margin character-
istics were more evident, or other char-
acteristic[s]), image noise, artifacts, con-
trast differences, technique differences,
uncertainty regarding the reason for the
greater visibility, or other reason(s). The
reader was asked to specify the other
characteristic(s) or other reason(s) when
these choices were checked.
Statistical Analyses
The seven readers provided 2211 opin-
ions regarding the differing visibility of
the 320 cancers included in our study.
One reader did not report on the visibility
of one lesion, so data from the remaining
2210 visibility ratings were analyzed. De-
scriptive tables summarizing the patient
and lesion characteristics were con-
structed. Overall reader preferences for
one modality over the other and the pos-
sible reasons for these preferences were
also summarized.
Multinomial logistic regression mod-
els were used to analyze the data (5). The
unit of analysis was lesion, and lesions
were considered independent. Since the
majority (294 [92%] of 320) of the cases
involved a single cancer, additional ad-
justment for multiple lesions in the same
patient was deemed unnecessary. How-
ever, through appropriate specification of
the covariance matrix in the analysis, the
correlations that resulted from several
observers reading images from the same
set of cases were accounted for in the
analysis. The response variable for the
logistic regression analysis—henceforth
referred to as the combined visibility rat-
ing—was a four-level categorical variable
created by condensing and combining the
visibility rankings for the digital and
screen-film images recorded for each can-
cer lesion by each reader. The four com-
bined visibility rating levels were defined
as follows: DG, indicating the cancer
was deemed to be more visible on the
Figure 1
Figure 1: Graphs illustrate condensed visibility rankings assigned by each reader according to breast
density. Rdr  reader.
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digital image than on the screen-film im-
age; SF, indicating the cancer was
deemed to be more visible on the screen-
film image than on the digital image;
DG  SF, indicating the cancer was
deemed to be equally visible on both im-
ages; and not visible, indicating the can-
cer was deemed to be not visible on either
image (Fig 1). The DG  SF category had
the highest frequency and was used as the
reference-standard rating level when
odds ratio (OR) inferences were drawn.
In addition, we fitted regular binary
logistic regression models by collapsing
levels of the combined visibility rating to
assess the odds of the assignment of DG
and SF ratings. These simplified models
did not measure up to the multinomial
models in terms of goodness of fit. The
results of the secondary binary analysis
corroborated the findings of the primary
multinomial analysis in direction and sta-
tistical significance and are not reported
here.
The primary model included breast
density (dichotomized with the two most
dense and the two least dense categories
combined), patient age (three levels), le-
sion type (four levels), machine type (five
levels), and reader (seven levels) as cate-
gorical covariates. A variant of this pri-
mary model, in which the covariate age
was excluded, was also examined. The
DMIST cancer characteristics included in
the models are listed in Table 1. Breast
density, machine type, and age were de-
termined by using DMIST data. Lesion
types were determined by a single reader
(E.D.P.). Those cases in which breast
cancer was not detected at digital or
screen-film mammography in the primary
DMIST were those in which the malig-
nancy was detected within the 455-day
follow-up period. These cases may have
had some findings—albeit quite subtle
ones—that were appreciable in retro-
spect by the reader who recorded the
lesion type in our study. This would ex-
plain the difference between the number
of cases in which cancers were not de-
tected with either modality at the time of
the original DMIST (n  93) and the num-
ber of cases in which findings were not
visible to the reader who recorded the
lesion types (n  35).
SAS, version 9.1.3, software (SAS,
Cary, NC) was used to perform the
analyses. For computational conve-
nience, separate binary baseline-logit
models—instead of a single multino-
mial logit model—were fitted by using
the PROC GENMOD (SAS) proce-
dure. Although separate fitting esti-
mates tend to be less efficient com-
pared with estimates from a simulta-
neous fitting, the loss in efficiency is
minor when the response category
with the highest prevalence is used as
the baseline category, as was done in
our analysis (6). The reported P values
are not based on hypothesis testing;
rather, they were used to assess whether
the reported model-based ORs were sig-
nificantly different from 1.
Results
The radiologist readers varied consid-
erably in their opinions regarding the
relative visibility of the cancers and
the reasons for the differences in vis-
ibility between screen-film and digital
mammography (Fig 1; Tables 2, 3).
For both the cancers in dense breasts
and those in fatty breasts, the most
frequent reason for the variability in
lesion visibility between the two mo-
dalities given by the readers was con-
trast differences between the two
examinations. For the women with
dense breasts, contrast differences ac-
counted for 70 (18.5%) of the 378 rea-
sons given by the readers that one mo-
Table 1
Characterization of 320 DMIST






Computed Radiography 59 (18.4)
Senographe 166 (51.9)
Lorad CCD-OT 3 (0.9)
Lorad Selenia-MG 14 (4.4)
Menopause status
Data missing 4 (1.2)

















Not seen† 47 (14.7)
1–3 O’clock 88 (27.5)
3–6 O’clock 27 (8.4)
6–9 O’clock 34 (10.6)
9–12 O’clock 91 (28.4)
Subareolar 10 (3.1)
Axillary tail 7 (2.2)
Superior 10 (3.1)
Inferior 3 (0.9)
Lateral in right breast,
medial in left breast 3 (0.9)
Medial in right breast,
lateral in left breast 0
Lesion type
No visible findings 35 (10.9)
Mass 137 (42.8)
Asymmetric density 29 (9.1)
Calcifications 104 (32.5)
Arch distortion 15 (4.7)
Cancer detection method
455-Day follow-up‡ 93 (29.1)
Digital and screen-film
mammography 122 (38.1)
Digital mammography only 56 (17.5)
(Table 1 continues)
Table 1 (continued)
Characterization of 320 DMIST






All cancers 320 (100)
Note.—Numbers in parentheses are percentages.
* Nondense refers to breasts composed almost entirely
of fat and breasts with scattered fibroglandular density.
Dense refers to heterogeneously dense and extremely
dense breasts.
† Cancer was not visible on screen-film or digital image,
so it could not be located in three dimensions.
‡ Cancer was not detected with either modality but
rather during the 455-day follow-up period.
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dality provided better visibility, with
the frequency of the other opinions
ranging from 0% to 8.5%. Positioning,
compression, and technique differ-
ences combined accounted for only 37
(9.8%) of the 378 reasons given for
improved lesion visibility.
Similar results were obtained for the
women with fatty breasts, with contrast
differences accounting for 52 (15.1%) of
345 opinions as to why one modality pro-
vided better visibility. However, in the
subset of women in whom screen-film
mammography depicted the cancers that
were missed with digital mammography,
the radiologists cited positioning differ-
ences as the reason for the improved le-
sion conspicuity in 25 (11.6%) of 216
cases. This compares with only five
(3.9%) of the 129 reasons and 12 (4.7%)
of the 253 reasons cited for the differ-
ences in conspicuity of cancers in the fatty
and dense breasts, respectively, that were
detected with digital mammography but
missed with screen-film mammography.
The better visibility of all cancers
judged by the readers to be more visible
Table 2
Radiologist Reasons for Cancer Visibility with One but Not the Other Modality










Positioning differences 12 (4.7) 9 (7.2) 21 (5.6) 5 (3.9) 25 (11.6) 30 (8.7)
Compression differences 2 (0.8) 5 (4.0) 7 (1.9) 3 (2.3) 7 (3.2) 10 (2.9)
Lesion located in dense tissue 24 (9.5) 5 (4.0) 29 (7.7) 2 (1.6) 0 2 (0.6)
Overlapping parenchyma obscurs lesions with one but
not the other modality 8 (3.2) 9 (7.2) 17 (4.5) 2 (1.6) 3 (1.4) 5 (1.5)
Lesion located in subcutaneous fat 0 0 0 0 1 (0.5) 1 (0.3)
Lesion located in thickest part of breast 1 (0.4) 0 1 (0.3) 0 2 (0.9) 2 (0.6)
Lesion characteristics more evident 22 (8.7) 10 (8.0) 32 (8.5) 6 (4.7) 19 (8.8) 25 (7.2)
More calcifications seen 17 7 24 4 4 8
Calcification shapes more obvious 5 5 10 1 3 4
Suspicious mass margin characteristics more evident 3 1 4 2 14 16
Other lesion characteristics more evident* 2 2 4 0 1 1
Image noise 5 (2.0) 3 (2.4) 8 (2.1) 1 (0.8) 4 (1.9) 5 (1.4)
Artifacts 0 0 0 0 1 (0.5) 1 (0.3)
Contrast differences 47 23 70 15 37 52
(18.6) (18.4) (18.5) (11.6) (17.1) (15.1)
Technique differences 5 (2.0) 4 (3.2) 9 (2.4) 4 (3.1) 12 (5.6) 16 (4.6)
Uncertain 0 0 0 0 5 (2.3) 5 (1.4)
All reasons 253 125 378 129 216 345
Note.—Data are numbers of cases of the given reason that a cancer lesion was visible with one modality but not with the other. Numbers in parentheses are percentages. Data pertain to cases
in which cancers were found with only one modality and are cited according to breast density and how the cancers were detected in the primary DMIST.
* When the reason “other lesion characteristics were more evident” was cited, the reader was asked to provide details.
Table 3
Radiologist Reasons for Better Cancer Visibility with One Modality Rather than the






Positioning differences 37 (16.7) 69 (29.7)
Compression differences 16 (7.2) 30 (12.9)
Lesion in dense tissue 37 (16.7) 20 (8.6)
Overlapping parenchyma obscured lesions with one but
not other modality 24 (10.9) 29 (12.5)
Lesion in subcutaneous fat 2 (0.9) 0
Lesion in thickest part of breast 4 (1.8) 2 (0.9)
Lesion characteristics more evident 59 (26.7) 60 (25.9)
More calcifications seen 37 30
Calcification shapes more obvious 20 17
Suspicious mass margin characteristics more evident 16 24
Other lesion characteristics more evident* 4 8
Image noise 0 28 (12.1)
Artifacts 0 1 (0.4)
Contrast differences 161 (72.8) 133 (57.3)
Technique differences 14 (6.3) 44 (19.0)
Uncertain 4 (1.8) 11 (4.7)
All reasons 221 232
Note.—Data are numbers of cases of the given reason that cancer lesion visibility was better with one modality rather than
the other, as cited for all analyzed cancers according to case review visibility results. Numbers in parentheses are percentages.
* When the reason “other lesion characteristics were more evident” was cited, the reader was asked to provide details.
BREAST IMAGING: Detection of Cancer in ACRIN Screening Trial Cases Pisano et al
352 radiology.rsnajnls.org ▪ Radiology: Volume 252: Number 2—August 2009
at digital mammography was attributed
most frequently to differences in image
contrast (161 [72.8%] of 221 opinions)
(Table 3). Other leading reasons that the
readers rated cancers to be more visible
on the digital images were more evident
lesion characteristics (59 [26.7%] of 221
opinions), location of lesion in dense tis-
sue (37 [16.7%] of 221 opinions), posi-
tioning differences (37 [16.7%] of 221
opinions), and overlapping parenchyma
obscuring the lesion on the screen-film
images (24 [10.9%] of 221 opinions).
Similar results were obtained for all
cancers judged to be more visible on the
screen-film images. Specifically, the most
common explanation for the greater visi-
bility was contrast differences, which ac-
counted for 133 (57.3%) of 232 opinions.
Other commonly mentioned reasons for
the greater visibility on the screen-film
images were positioning differences (69
[29.7%] of 232 opinions), more evident
lesion characteristics (60 [25.9%] of 232
opinions), overlapping parenchyma ob-
scuring the lesion on the digital images
(29 [12.5%] of 232 opinions), technique
differences (44 [19.0%] of 232 opinions),
and image noise (28 [12.1%] of 232 opin-
ions).
The results of the two models are pre-
sented in Table 4. Both models included
machine type and lesion type as covari-
ates. In addition, model A included the
dichotomized breast density variable.
Model B included age. Our analyses re-
vealed that when the breasts were dense,
the readers were twice as likely to rate a
cancer as more visible on the digital im-
ages than to rate a cancer as equally vis-
ible on the digital and screen-film images
(OR, 2.28; 95% CI: 1.61, 3.23; P 
.0001). There was a nonsignificant ten-
dency of the readers to rate lesion visibil-
ity as superior on the screen-film mam-
mograms for fatty breasts.
The odds of a cancer being more vis-
ible on the screen-film image rather than
being equally visible on both the screen-
film and digital images were significantly
lower for women between ages 50 and 64
years than for women aged 65 years or
older, regardless of breast density. The
model also revealed that the odds of the
radiologists rating lesions as more visible
on the digital image rather than rating
lesions as equally visible on both images
were significantly lower when the Fischer
(OR, 0.52; 95% CI: 0.33, 0.84; P 
.0070) and Fuji (OR, 0.55; 95% CI: 0.35,
0.85; P  .0070) systems were used than
when the General Electric machine was
used, regardless of patient age and breast
density. The odds of screen-film mam-
mography receiving a better visibility rat-
ing rather than digital and screen-film
mammography having equal visibility rat-
ings were higher when the Fischer digital
system was used (OR, 1.89; 95% CI:
1.35, 2.64; P  .0002) than when the
General Electric system was used. These
odds were lower when the Fuji digital sys-
tem was used (OR 0.40; 95% CI: 0.24,
0.67; P  .0005) compared with when
the General Electric machine was used,
regardless of patient age. The nonsignifi-
cant tendency toward better lesion visibil-
ity with screen-film mammography in
older women with fatty breasts was
higher with use of the Fischer system
than with use of the Fuji and General
Electric systems (Table 5).
Reader identity also significantly af-
fected the likelihood of digital mammog-
raphy having a higher visibility rating than
screen-film mammography. Four readers
Table 4
Logistic Regression Analyses Results
DG vs SF  DG SF vs SF  DG
Variables and Covariates Model A Model B Model A Model B
Mammography system
Senographe*
Senoscan-Dx 0.52 (0.33, 0.84) 0.52 (0.33, 0.84) 1.88 (1.35, 2.62) 1.89 (1.35, 2.64)
.0068† .0070† .0002† .0002†
Computed Radiography 0.55 (0.36, 0.84) 0.55 (0.35, 0.85) 0.39 (0.24, 0.66) 0.40 (0.24, 0.67)
.0064† .0070† .0004† .0005†
Lorad CCD-OT 0.94 (0.19, 4.70) 1.02 (0.20, 5.23) 0.58 (0.07, 4.60) 0.46 (0.06, 3.72)
.9396 .9800 .6052 .4698
Lorad Selenia-MG 1.30 (0.64, 2.63) 1.34 (0.66, 2.74) 0.92 (0.39, 2.15) 0.85 (0.36, 2.00)
.4719 .4230 .8407 .7107
Lesion type
Mass*
Arch distortion 1.26 (0.63, 2.54) 1.20 (0.59, 2.43) 1.08 (0.54, 2.14) 1.11 (0.56, 2.20)
.5159 .6118 .8331 .7680
Asymmetric densities 1.40 (0.75, 2.62) 1.41 (0.75, 2.65) 1.27 (0.66, 2.44) 1.24 (0.64, 2.39)
.2928 .2813 .4801 .5251
Calcification 1.35 (0.95, 1.92) 1.36 (0.96, 1.95) 1.13 (0.82, 1.57) 1.14 (0.82, 1.59)
.0898 .0862 .4585 .4257
Breast density
Fatty*
Dense 2.25 (1.61, 3.15) 2.28 (1.61, 3.23) 1.11 (0.82, 1.52) 1.17 (0.85, 1.61)
.0001† .0001† .4906 .3414
Age (y)
65*
50 . . . 0.86 (0.52, 1.43) 0.87 (0.57, 1.34)
.5621 .5317
50–64 . . . 1.24 (0.83, 1.86) 0.64 (0.45, 0.92)
.2858 .0142†
Note.—For each data set, the first set of numbers are ORs, with 95% confidence intervals (CIs) in parentheses. The second
numbers are P values, which reflect the statistical difference in the OR from 1. DG vs SF  DG refers to comparison of case
in which cancer is more visible on the digital image than on the screen-film image versus case in which cancer is equally
visible on both images. SF vs SF  DG refers to comparison of case in which cancer is more visible on the screen-film image
than on the digital image versus case in which cancer is equally visible on both images.
* Reference-standard variable with which covariate or covariates were compared.
† Significant difference in OR from 1.
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were more likely to rate screen-film im-
aging higher than digital imaging, and
three were more likely to rate digital im-
aging higher. Lesion type did not signifi-
cantly affect the visibility ratings of the
two modalities.
Figure 2 shows an example of a
DMIST case in which a cancer was de-
tected at digital mammography but
missed at screen-film mammography.
Figure 3 shows an example of a DMIST
case in which a cancer was detected on
the screen-film images but missed on
the digital images and in which a differ-
ent image processing algorithm (Pre-
mium View) has been applied. We in-
clude this case here to demonstrate the
effect of image contrast on cancer visi-
bility.
Discussion
Our analysis suggests that image contrast
was the most important factor in the im-
proved performance of digital mammog-
raphy, as compared with screen-film
mammography, in DMIST. Similarly,
where DMIST suggested a trend toward
better accuracy with screen-film mam-
mography than with digital mammogra-
phy, image contrast again seemed to be a
strong contributing factor. The decre-
ment in lesion visibility in the fatty breasts
with digital mammography that was at-
tributed to image contrast was most
marked for those cases acquired by using
the Fischer system. In addition, position-
ing differences more frequently contrib-
uted to the nonsignificant trend in im-
proved cancer visibility for screen-film
mammography relative to digital mammog-
raphy in the women with fatty breasts.
How might digital mammography
yield contrast that is superior to that of
screen-film mammography in women
with dense breasts while exhibiting infe-
rior contrast in women with fatty
breasts? The factors that affect image
contrast in digital mammography include
the choice of the x-ray spectrum, the ef-
ficiency of the x-ray scatter rejection,
and display image processing. In
DMIST, these factors varied some-
what by machine type (7–9).
In addition, the nature and quality
of the image data processing varied
considerably. The visibility of lesion
features is influenced substantially by
the image processing algorithm and
whether the lesion lies within a dense
or fatty background (10). We believe
that this is the most likely explanation
for the conflicting results for dense
and fatty breasts. The linear relation-
ship between x-ray exposure and im-
age signal that is achievable with dig-
ital detectors should allow inherently
better image contrast (11).
We hypothesize that the manufactur-
ers of the digital mammography systems
focused their efforts on designing image
processing algorithms that improve the
gray scale in dense breasts while rela-
tively deemphasizing the optimization of
image processing in fatty breasts. This
might seem justified since screen-film
mammography misses more cancers in
patients with dense breasts while having
high sensitivity in fatty breasts (12,13). In
addition, radiologists may behave differ-
ently when they interpret mammograms
of fatty breasts compared with when they
interpret mammograms of dense breasts
because they know that lesions can hide
in dense breasts. Readers may just spend
more time evaluating dense breasts.
Of particular interest, given the re-
sults of our recently published DMIST
cost-effectiveness analysis (14), which
showed that digital mammography per-
formed in patients older than 65 years is
not cost-effective, is the excess number of
cases of mammography performed with
the Fischer system, which is no longer
commercially available, among the can-
cers that were seen better on screen-film
than digital images. Several factors re-
lated to the design of this system may
have been responsible for the reduced
performance in fatty breasts: The detec-
tor comprised a charge-coupled device
with an x-ray absorbing phosphor. The
Table 5










Cancer not seen* 2/43 (5) 9/43 (21) 27/43 (63) 0 5/43 (12) 43/43 (100)
2/75 (3) 9/77 (12) 27/270 (10) 0 5/12 (42) 43/441 (10)
Cancer seen
Equally on both images 52/318 (16) 62/318 (20) 192/318 (60) 6/318 (2) 6/318 (2) 318/318 (100)
52/75 (69) 62/77 (81) 192/270 (71) 6/7 (86) 6/12 (50) 318/441 (72)
Better on digital images 1/29 (3) 2/29 (7) 26/29 (90) 0 0 29/29 (100)
1/75 (1) 2/77 (3) 26/270 (10) 0 0 29/441 (7)
Better on screen-film images 20/51 (39) 4/51 (8) 25/51 (49) 1/51 (2) 1/51 (2) 51/51 (100)
20/75 (27) 4/77 (5) 25/270 (9) 1/7 (14) 1/12 (8) 51/441 (12)
All cancers 75/441 (17) 77/441 (18) 270/441 (61) 7/441 (2) 12/441 (3)
75/75 (100) 77/77 (100) 270/270 (100) 7/7 (100) 12/12 (100) 441/441 (100)
Note.—Data are numbers of cases ranked for cancer visibility according to the digital mammography system used to assess the cases for cancer. For each data set, the top set of numbers is the
number of cases and percentage based on the total number of cancers seen and not seen, and the bottom set is the number of cases and percentage based on the total number of cases assessed
with the different mammography systems.
* Cancer was not visible with either screen-film or digital mammography.
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digitization was limited to 12 bits or 4096
gray levels, whereas the other systems
typically provide the equivalent of 14 bits
or 16 384 gray levels. With the 12-bit
digitization of the Fischer system, to avoid
overdriving the digital detector past its
maximal value, the user operated the de-
tector in the lower part of its range, pos-
sibly resulting in increased image noise.
In addition, the Fischer system did
not have an automatic exposure control,
so technologists had to guess the breast
density to set the exposure level. The lim-
ited dynamic range of the detector prob-
ably made it more difficult to optimize
image display, possibly resulting in poor
contrast. Finally, the tungsten-aluminum
x-ray spectrum provided excellent pene-
tration of the dense breast and allowed
low radiation doses to be used. For the
fatty breasts, however, the more pene-
trating x-ray spectrum of the Fischer sys-
tem may have been a detriment.
Our study demonstrates that the re-
sults obtained in DMIST were not due
primarily to accidents in positioning or
interpretation (15,16). That is, digital
mammography performed significantly
better in particular subsets of women be-
cause of the better conspicuity of lesions
in those subgroups. Screen-film mam-
mography tended nonsignificantly to per-
form better in the subset of women aged
65 years or older with fatty breasts be-
cause of the improved conspicuity of le-
sions on film hard-copy images in this
subgroup. This suggests that digital sys-
tem manufacturers should improve the
quality of their image processing algo-
rithms, especially for fatty breasts—
perhaps by applying different algorithms,
for different breast densities, ideally
based on reader performance data and
not simply aesthetic factors (10).
A limitation of our analysis was the
inclusion of very few cancers that were
detected by using the Hologic systems,
which reduced the power of our analysis
for these units. In addition, our study re-
ports on the opinions of radiologist read-
ers. The basis for differences in opinion
among readers is unclear and may include
personal preferences, the amount of ex-
perience the readers had with both mo-
dalities and/or with specific machine
types, and the availability of newer image
processing algorithms for viewing some
cases. Newer image processing algo-
rithms perhaps explain the performance
of the General Electronic system relative
to the performance of the Fuji and Fischer
units, since all readers had experience with
that system and the Premium View algo-
rithm was available for all General Elec-
tronic cases evaluated in this study but only
for a 4-month period in DMIST itself.
Figure 2
Figure 2: Craniocaudal mammographic views of dense left breast in 52-year-old-woman. (a) Full digital
mammogram obtained by using Senographe system and (c) close-up view of area outlined (in rectangle) in
a, as compared with (b) full screen-film mammogram of same breast and (d) close-up view of area outlined (in
rectangle) in b, reveal how improved contrast in dense part of the breast depicted on the digital mammogram
enables visualization of the cancer, an invasive ductal carcinoma, on the digital image but not on the screen-
film image. The lesion was not visible on either the mediolateral oblique screen-film or digital mammograms.
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Figure 3
Figure 3: Fatty breast depicted on (a, d, g) screen-film and (b, c, e, f, h, i) digital left mammograms obtained in 53-year-old woman. Cancerous areas are outlined in
rectangles. (a–f) Mediolateral oblique and (g–i) craniocaudal views are shown. The cancer, a mass that proved to be an invasive ductal carcinoma, is much more appar-
ent on the screen-film images than on the digital images, with visibility being greatest on the screen-film mediolateral oblique views. The difference in lesion visibility
between the screen-film and digital mammograms is accentuated when the screen-film overview image (a) is compared with the digital overview image obtained by using
the default image processing algorithm (b). Close-up views of cancerous areas outlined in a (d) and b (e) are shown. There is a slight improvement in the visibility of the
lesion depicted at digital mammography performed by using the Premium View image processing software, as seen on digital mediolateral oblique overview (c), screen-
film mediolateral oblique close-up view (d), and digital craniocaudal (i) images.
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Three of the four manufacturers con-
tributed nearly equally to the significant
findings in favor of digital mammography
in the women with dense breasts and the
women younger than 50 years, while we
suspect that the relatively weaker perfor-
mance of digital imaging in the women
with fatty breasts was attributable pri-
marily to the use of the Fischer machine.
How the machines performed relative to
each other cannot be determined with
certainty from these data because differ-
ent women were examined with each ma-
chine. In conclusion, the DMIST results
are most likely attributable to differences
in image contrast between the two modal-
ities—not to positioning or reader vari-
ability factors.
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